Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Neoplasms of the CNS

Free Subscription Articles published in J Neuropathol Exp Neurol Retrieve available abstracts of 104 articles: HTML format

Single Articles

June 2026
1. WEN Y, He Y, Li J, Zhou H, et al
   Comprehensive identification of FoxO signaling as a promising prognostic and immunotherapeutic biomarker in glioma.
   J Neuropathol Exp Neurol. 2026 Jun 2:nlag059. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2026
2. SUN Y, Jia Y, Bu X, Chen Y, et al
   Leucine-rich pentatricopeptide repeat-containing protein silencing transcriptionally regulated by GATA-binding protein 3 has an anti-glioma effect by regulating glycolysis and ferroptosis by mediating N6-methyladenosine modification of protocadherin-7
   J Neuropathol Exp Neurol. 2026 May 4:nlag043. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. HIGA N, Akahane T, Yokoyama S, Yonezawa H, et al
   Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.
   J Neuropathol Exp Neurol. 2026;85:455-463.
   PubMed     Abstract available
   
   
   March 2026
4. KAHR J, Diaz-Peregrino R, Sandalcioglu IE, John P, et al
   RagC and Map4K3 deficiency in high-grade gliomas drives proliferation and modulates mTORC1-dependent cellular functions.
   J Neuropathol Exp Neurol. 2026 Mar 22:nlag010. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. SPYRETOS C, Pardo Ladino JM, Andersen Blomstrand H, Nyman P, et al
   Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.
   J Neuropathol Exp Neurol. 2026 Mar 10:nlaf163. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. EBNER BA, Ida CM, Kollmeyer TM, Jenkins RB, et al
   Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
   J Neuropathol Exp Neurol. 2026 Mar 9:nlag007. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. COTY-FATTAL Z, Smith H, McCord M, Mejia-Bautista M, et al
   Rapid assessment of MGMT promoter methylation status by droplet digital polymerase chain reaction on intraoperative smear preparation: A proof-of-concept study.
   J Neuropathol Exp Neurol. 2026;85:280-284.
   PubMed     Abstract available
   
   
   February 2026
8. NISHIDA N, Hata Y
   Sudden unexpected death associated with previously undiagnosed gliomas: A mechanism-based interpretation of three autopsy cases.
   J Neuropathol Exp Neurol. 2026 Feb 14:nlag006. doi: 10.1093.
   PubMed    
   
   
   
9. GRAY MT, Cayrol R, May A, Skaugen JM, et al
   Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis.
   J Neuropathol Exp Neurol. 2026 Feb 4:nlag004. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2026
10. YUAN J, Liu H, Wen J, Zhao Z, et al
    Cardiotrophin-like cytokine factor 1 regulated by Sry-related HMG-box transcription factor 9 promotes malignant behavior and immune evasion of glioblastoma multiforme.
    J Neuropathol Exp Neurol. 2026 Jan 19:nlaf161. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. VOYLES C, Bellizzi AM, Lopes Abath Neto O
    Survival analysis of brain-invasive otherwise benign meningiomas in a single-institution cohort.
    J Neuropathol Exp Neurol. 2026 Jan 12:nlaf157. doi: 10.1093.
    PubMed    
    
    
    December 2025
12. FUKUOKA K, Irikura T, Kanemura Y, Hirato J, et al
    Intratumoral heterogeneity of MYC status and methylation subtyping in group 3 medulloblastoma: A case report.
    J Neuropathol Exp Neurol. 2025 Dec 23:nlaf153. doi: 10.1093.
    PubMed    
    
    
    
13. MAFFICINI A, Pigato F, Miele E, Patrizi S, et al
    Fumarate hydratase-mutant glioma with giant-cell histology, MSH6 mutation, and hypermutation.
    J Neuropathol Exp Neurol. 2025 Dec 9:nlaf142. doi: 10.1093.
    PubMed    
    
    
    
14. CHIANG WY, Li X, Tanaka R, Chiang J, et al
    Activated signaling pathways and metabolic processes in disseminating myxoid glioneuronal tumors.
    J Neuropathol Exp Neurol. 2025;84:1106-1112.
    PubMed     Abstract available
    
    
    November 2025
15. BELAKHOUA S, Lopez G, Dubey S, Rai S, et al
    RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications.
    J Neuropathol Exp Neurol. 2025 Nov 29:nlaf129. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. BROECHNER A, Maier AD, Mirian C, Sahm F, et al
    Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.
    J Neuropathol Exp Neurol. 2025 Nov 20:nlaf131. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. WELCH RL, Fluss RS, Yokoda RT, Himes BT, et al
    Primary sporadic intracranial DICER1 mutant sarcoma with SSTR2 positivity in an adult patient mimicking anaplastic meningioma.
    J Neuropathol Exp Neurol. 2025 Nov 11:nlaf053. doi: 10.1093.
    PubMed    
    
    
    
18. WENG M, Zhu X
    FOXM1/CENPI axis regulation of proline and arginine metabolism in glioblastoma cells.
    J Neuropathol Exp Neurol. 2025 Nov 4:nlaf121. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2025
19. MANDARA MT, Giglia G, Benedetti G, Falzone C, et al
    Tumor-associated macrophages in feline meningiomas: Exploring their prognostic significance.
    J Neuropathol Exp Neurol. 2025 Oct 21:nlaf119. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. MURAYI R, El-Abtah M, Ejikeme T, Xiao T, et al
    Validation of an immunohistochemistry-based molecular group stratification of intracranial meningiomas.
    J Neuropathol Exp Neurol. 2025 Oct 15:nlaf120. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2025
21. GUO Y, Liu H, Gao Z, Zhou Z, et al
    Mitochondrial dysfunction and its impact on pyroptosis and ferroptosis cross talk in glioma cells.
    J Neuropathol Exp Neurol. 2025 Sep 17:nlaf099. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. VOONG V, Beccari S, Hashemi E, Kriener B, et al
    3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma.
    J Neuropathol Exp Neurol. 2025 Sep 3:nlaf101. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
23. ZHANG Z, Guo X, Qi T, Wang C, et al
    METTL14/IGF2BP2-mediated m6A modification of PD-L1 promotes proliferation, metastasis, and immune escape in high-grade gliomas.
    J Neuropathol Exp Neurol. 2025 Aug 11:nlaf090. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
24. HAO Z, Han Y, Bo Y, Cao L, et al
    Knocking down RFWD3 suppresses the growth and migration of glioblastoma cells by blocking G2/M cycle progression.
    J Neuropathol Exp Neurol. 2025 Jul 23:nlaf087. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. LIECHTY B, Kim S, Dobri G, Schwartz TH, et al
    SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.
    J Neuropathol Exp Neurol. 2025;84:626-633.
    PubMed     Abstract available
    
    
    
26. HARPER SD, Perryman T, Dudley LA, Prabhu AS, et al
    Molecular characterization of benign intracranial glioependymal and arachnoid cysts suggest heterogeneous mechanisms of action.
    J Neuropathol Exp Neurol. 2025;84:617-625.
    PubMed     Abstract available
    
    
    
27. SIDDIQ Z, Gilani A, Ung TH, Kleinschmidt-DeMasters BK, et al
    Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young.
    J Neuropathol Exp Neurol. 2025;84:611-616.
    PubMed     Abstract available
    
    
    June 2025
28. LOCHNER RH, Powell SZ, Fung KM, Zhang YJ, et al
    FGFR1 fusions in genomically and epigenetically bona fide glioblastoma, IDH-wildtype.
    J Neuropathol Exp Neurol. 2025 Jun 12:nlaf068. doi: 10.1093.
    PubMed    
    
    
    
29. TERRY M, Reis G, Pekmezci M, Phillips JJ, et al
    PAS+/PASD- intracytoplasmic glycogen is not specific for clear cell meningioma.
    J Neuropathol Exp Neurol. 2025 Jun 6:nlaf065. doi: 10.1093.
    PubMed    
    
    
    May 2025
30. TOLLEFSEN SE, Meta R, Solheim O, Mjones P, et al
    Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf058. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. TAUZIEDE-ESPARIAT A, Rousseau A, Basset L, Saffroy R, et al
    A comparison of CDKN2A status in gliomas using different techniques: The loss of p16 as a surrogate marker.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf062. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. FURUTA T, Miyoshi H, Moritsubo M, Nakajima R, et al
    Biological role and clinicopathological significance of leucine-rich alpha-2 glycoprotein 1 in the glioblastoma microenvironment.
    J Neuropathol Exp Neurol. 2025 May 9:nlaf049. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. ROBINS SM, Rosenblatt M, Bruce JN, Canoll P, et al
    Solitary fibrous tumor in the pineal region: A series of 5 cases and literature review.
    J Neuropathol Exp Neurol. 2025;84:379-390.
    PubMed     Abstract available
    
    
    April 2025
34. COOK DJ, Decker PA, Hardcastle JJ, Kollmeyer TM, et al
    EGFR transcript variants: Potential diagnostic biomarker for glioblastoma, IDH-wildtype?
    J Neuropathol Exp Neurol. 2025 Apr 25:nlaf041. doi: 10.1093.
    PubMed    
    
    
    
35. UGWUOWO U, Faust B, Tang H, DiStasio M, et al
    Adequate capture of spatial heterogeneity of Ki-67 proliferative index in meningiomas requires multiple tissue sections.
    J Neuropathol Exp Neurol. 2025 Apr 21:nlaf043. doi: 10.1093.
    PubMed    
    
    
    
36. DONO A, Pichardo-Rojas D, Mendoza Mora L, Pichardo-Rojas PS, et al
    MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review.
    J Neuropathol Exp Neurol. 2025 Apr 18:nlaf033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. LI Y, Shen X, Zhang J, Xian X, et al
    Adult diffuse IDH-wildtype lower-grade gliomas with PDGFRA gain/amplification should be upgraded as glioblastoma.
    J Neuropathol Exp Neurol. 2025 Apr 16:nlaf039. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. NGUYEN P, Yokoda RT, Hossain Q, Bederson JB, et al
    Solitary fibrous tumor-meningioma collision tumor with 18 years of follow-up.
    J Neuropathol Exp Neurol. 2025 Apr 11:nlaf037. doi: 10.1093.
    PubMed    
    
    
    February 2025
39. MORENO-TORRES B, Manzano-Benito I, Cantero D, Romo A, et al
    Integrating molecular analyses with the 2021 WHO classification of adult pilocytic astrocytomas.
    J Neuropathol Exp Neurol. 2025;84:255-263.
    PubMed     Abstract available
    
    
    December 2024
40. CHEN A, Hart SL, Lannon M, Hawkins C, et al
    Meningiomas in Rubinstein-Taybi syndrome: A case report and comprehensive review.
    J Neuropathol Exp Neurol. 2024 Dec 31:nlae135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. VIZCAINO MA, Giannini C, Vaubel RA, Nguyen AT, et al
    Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.
    J Neuropathol Exp Neurol. 2024;83:1003-1009.
    PubMed     Abstract available
    
    
    November 2024
42. GUO Y, Li Y, Su P, Yan M, et al
    Tumor microtubes: A new potential therapeutic target for high-grade gliomas.
    J Neuropathol Exp Neurol. 2024 Nov 19:nlae119. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
43. SHEKARIAN T, Ritz MF, Hogan S, Martins TA, et al
    Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse.
    J Neuropathol Exp Neurol. 2024 Oct 18:nlae108. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. CECCHI R, Guptil D, Haslett N, Hristov A, et al
    Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results.
    J Neuropathol Exp Neurol. 2024;83:882-886.
    PubMed    
    
    
    September 2024
45. OHARA K, Al Assaad M, McNulty SN, Alnajar H, et al
    Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.
    J Neuropathol Exp Neurol. 2024 Sep 28:nlae105. doi: 10.1093.
    PubMed    
    
    
    
46. REIMANN RR, Gramatzki D, Bink A, Hench J, et al
    Long survival in a patient with fumarate hydratase mutation-associated glioma.
    J Neuropathol Exp Neurol. 2024 Sep 16:nlae100. doi: 10.1093.
    PubMed    
    
    
    
47. KLEINSCHMIDT-DEMASTERS BK
    Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights.
    J Neuropathol Exp Neurol. 2024;83:708-721.
    PubMed     Abstract available
    
    
    
48. FENG Y, Wong PJC, Fu M, Kong Y, et al
    The comprehensive morphological and molecular characteristics of lipoastrocytoma: A case report.
    J Neuropathol Exp Neurol. 2024;83:785-790.
    PubMed    
    
    
    August 2024
49. WANG C, Han H, Cheng F, Wang H, et al
    Clinical significance and potential mechanism of AEBP1 in glioblastoma.
    J Neuropathol Exp Neurol. 2024 Aug 27:nlae091. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. TIAN S, Xie G, Zhang H, Zuo F, et al
    A heritable form of SMARCE1-related meningiomas with clinical implications.
    J Neuropathol Exp Neurol. 2024 Aug 19:nlae080. doi: 10.1093.
    PubMed    
    
    
    
51. MORRIS M, Ararat K, Cutshall H, Gokden M, et al
    SMARCA4-deficient central nervous system metastases: A case series and systematic review.
    J Neuropathol Exp Neurol. 2024;83:638-654.
    PubMed     Abstract available
    
    
    
52. ABOUBAKR O, Senova S, Kauv P, Castel D, et al
    A non-midline unclassified glioneuronal tumor with H3K27M mutation enlarging the spectrum of CNS tumors H3K27ME3-altered.
    J Neuropathol Exp Neurol. 2024;83:701-705.
    PubMed    
    
    
    July 2024
53. TANAKA Y, Natsumeda M, Ohashi M, Saito R, et al
    Primary spinal cord gliomas: Pathologic features associated with prognosis.
    J Neuropathol Exp Neurol. 2024 Jul 29:nlae084. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. ALTURKUSTANI M, Walker AD, Castaneda EA, Cotter JA, et al
    Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology.
    J Neuropathol Exp Neurol. 2024 Jul 27:nlae082. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. KANATHANAVANICH M, Koga S, Stone SL, Roth J, et al
    CTDSP2::GLI1 fusion in glioblastoma: A diagnostic challenge through tumor heterogeneity.
    J Neuropathol Exp Neurol. 2024 Jul 9:nlae073. doi: 10.1093.
    PubMed    
    
    
    
56. LE MK, Tran NQV, Nguyen PT, Nguyen TA, et al
    Comprehensive analysis of distinct circadian clock subtypes of adult diffuse glioma and their associations with clinicopathological, genetic, and epigenetic profiles.
    J Neuropathol Exp Neurol. 2024 Jul 4:nlae055. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. FENG K, Ye G, Wang H, Li S, et al
    Research on the mechanism of TWSG1 in the malignant progression of glioma cells and tumor-associated macrophage infiltration.
    J Neuropathol Exp Neurol. 2024 Jul 1:nlae067. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
58. KISELJAK-VASSILIADES K, Lipe K, Turin CG, Fishbein L, et al
    E-cadherin expression and gene expression profiles in corticotroph pituitary neuroendocrine tumor subtypes.
    J Neuropathol Exp Neurol. 2024;83:586-595.
    PubMed     Abstract available
    
    
    
59. PARKER M, Kazemi F, Krishnakumar A, Horowitz MA, et al
    Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.
    J Neuropathol Exp Neurol. 2024;83:579-585.
    PubMed     Abstract available
    
    
    
60. ZSCHERNACK V, Thomas C, Schaub C, Kristiansen G, et al
    FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.
    J Neuropathol Exp Neurol. 2024 Jun 14:nlae064. doi: 10.1093.
    PubMed    
    
    
    
61. LORETO PALACIO P, Pan X, Jones D, Otero JJ, et al
    Exploring a distinct FGFR2::DLG5 rearrangement in a low-grade neuroepithelial tumor: A case report and mini-review of protein fusions in brain tumors.
    J Neuropathol Exp Neurol. 2024 Jun 4:nlae040. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
62. SHIBAHARA I, Nakashima T, Toyoda M, Inukai M, et al
    Evolving driver mutations in adult-onset SHH-medulloblastoma originated from radiological cerebellar abnormality.
    J Neuropathol Exp Neurol. 2024 May 29:nlae051. doi: 10.1093.
    PubMed    
    
    
    
63. VIZCAINO MA, Giannini C, Lalich D, Nael A, et al
    Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    J Neuropathol Exp Neurol. 2024;83:416-424.
    PubMed     Abstract available
    
    
    April 2024
64. MACRAE CB, Grieco KC, Solomon IH
    Diagnostic yield of postmortem brain examination following premortem brain biopsy for neoplastic and nonneoplastic disease.
    J Neuropathol Exp Neurol. 2024;83:331-337.
    PubMed     Abstract available
    
    
    
65. WILCOCK DM, Goold E, Zuromski LM, Davidson C, et al
    EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
    J Neuropathol Exp Neurol. 2024 Apr 11:nlae028. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
66. KALTER JA, Yang RA, Toland A, Milla S, et al
    IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy.
    J Neuropathol Exp Neurol. 2024;83:289-292.
    PubMed    
    
    
    
67. NEWMAN J, Leelatian N, Liang J
    Characterization of pediatric non-hematopoietic tumor metastases to the central nervous system: A single institution review.
    J Neuropathol Exp Neurol. 2024;83:268-275.
    PubMed     Abstract available
    
    
    
68. DONEV K, Sundararajan V, Johnson D, Balan J, et al
    Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    J Neuropathol Exp Neurol. 2024 Mar 6:nlae018. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
69. QI P, Yao QL, Lao IW, Ren M, et al
    A custom next-generation sequencing panel for 1p/19q codeletion and mutational analysis in gliomas.
    J Neuropathol Exp Neurol. 2024 Feb 26:nlae011. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. KRAUSE KA, Woods JK, Golby AJ, Lee EQ, et al
    Progestin-associated meningiomatosis with unusual schwannoma-like morphology.
    J Neuropathol Exp Neurol. 2024 Feb 1:nlae008. doi: 10.1093.
    PubMed    
    
    
    January 2024
71. XI S, Huang Q, Zeng J
    A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2024;83:125-130.
    PubMed     Abstract available
    
    
    
72. FENG Y, Xu H, Hu X, Zhang J, et al
    Heterogenous driving genetic events contribute to the dissemination of choroid plexus papilloma.
    J Neuropathol Exp Neurol. 2024;83:131-135.
    PubMed    
    
    
    
73. MARIET C, Grill J, Ajlil Y, Castel D, et al
    "Hemispheric pilocytic astrocytoma" revisited: A comprehensive clinicopathological and molecular series emphasizing their overlap with other glioneuronal tumors.
    J Neuropathol Exp Neurol. 2024;83:115-124.
    PubMed     Abstract available
    
    
    
74. ABOUBAKR O, Metais A, Doz F, Saffroy R, et al
    LEF-1 immunohistochemistry, a better diagnostic biomarker than beta-catenin for medulloblastoma, WNT-activated subtyping.
    J Neuropathol Exp Neurol. 2024 Jan 17:nlad104. doi: 10.1093.
    PubMed    
    
    
    
75. GUBBIOTTI MA, Weinberg JS, Weathers SP, Dasgupta P, et al
    An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation.
    J Neuropathol Exp Neurol. 2024 Jan 2:nlad114. doi: 10.1093.
    PubMed    
    
    
    December 2023
76. ROBINSON LJ, Goold E, Potter S, Quigley EP, et al
    A pleomorphic xanthoastrocytoma highlighting the morphological heterogeneity of this uncommon tumor.
    J Neuropathol Exp Neurol. 2023;83:61-64.
    PubMed    
    
    
    
77. GUNDOGDU F, Babaoglu B, Soylemezoglu F
    Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
    J Neuropathol Exp Neurol. 2023 Dec 18:nlad109. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
78. GESTRICH C, Grieco K, Lidov HG, Baird LC, et al
    H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
    J Neuropathol Exp Neurol. 2023 Nov 30:nlad103. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. HUA Y, Youens KE, Castro E, Wang D, et al
    Autopsy findings in a 6-month-old infant with rhabdoid tumor predisposition syndrome 1: Case report with literature review.
    J Neuropathol Exp Neurol. 2023;82:1040-1043.
    PubMed    
    
    
    
80. WHITE B, Filo J, Orrego-Gonzalez E, Schwartz SN, et al
    Synchronous contralateral low-grade oligodendroglioma and high-grade IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:1048-1050.
    PubMed    
    
    
    
81. NUECHTERLEIN N, Shelbourn A, Cimino PJ
    Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes.
    J Neuropathol Exp Neurol. 2023 Nov 14:nlad092. doi: 10.1093.
    PubMed    
    
    
    
82. BLUM N, Mirian C, Maier AD, Mathiesen TI, et al
    Translocator protein (TSPO) expression in neoplastic cells and tumor-associated macrophages in meningiomas.
    J Neuropathol Exp Neurol. 2023 Nov 11:nlad093. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2023
83. NAZEM A, Lavezo J, Abdullaev Z, Aldape K, et al
    Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
    J Neuropathol Exp Neurol. 2023 Oct 25:nlad089. doi: 10.1093.
    PubMed    
    
    
    
84. ABOUBAKR O, Metais A, Hasty L, Saffroy R, et al
    Brainstem oligodendroglioma, IDH-mutant, and 1P/19Q-codeleted: A potential diagnostic pitfall.
    J Neuropathol Exp Neurol. 2023;82:958-962.
    PubMed    
    
    
    
85. CAO C, Zhang L, Sorensen MD, Reifenberger G, et al
    D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.
    J Neuropathol Exp Neurol. 2023;82:921-933.
    PubMed     Abstract available
    
    
    
86. SHELBOURN A, Nuechterlein N, Parada CA, Eaton J, et al
    Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype.
    J Neuropathol Exp Neurol. 2023 Oct 13:nlad082. doi: 10.1093.
    PubMed    
    
    
    
87. KOLEILAT A, Kumar V, Al Hmada Y, Milosevic D, et al
    Concurrent TERT promoter C228T and C250T mutations in diffuse gliomas: Rare occurrence of intratumoral heterogeneity.
    J Neuropathol Exp Neurol. 2023 Oct 9:nlad081. doi: 10.1093.
    PubMed    
    
    
    September 2023
88. XU E, Stone SL, Zhong Y, Golenberg N, et al
    A novel ARIH1::BRAF fusion in a glioma.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad074. doi: 10.1093.
    PubMed    
    
    
    
89. ZHANG Y, Huang H, Liu P, Xie Y, et al
    NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad073. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. YOKODA RT, Cobb WS, Yong RL, Crary JF, et al
    CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:845-852.
    PubMed     Abstract available
    
    
    June 2023
91. GUBBIOTTI MA, Madsen PJ, Tucker AM, Abdullaev Z, et al
    ZFTA-fused supratentorial ependymoma with a novel fusion partner, DUX4.
    J Neuropathol Exp Neurol. 2023;82:668-671.
    PubMed    
    
    
    
92. MAIER AD, Christiansen SN, Haslund-Vinding J, Krogager ME, et al
    DNA methylation profile of human dura and leptomeninges.
    J Neuropathol Exp Neurol. 2023;82:641-649.
    PubMed     Abstract available
    
    
    
93. FUKUOKA K, Nakazawa A, Hirato J, Nobusawa S, et al
    An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation.
    J Neuropathol Exp Neurol. 2023;82:664-667.
    PubMed    
    
    
    
94. BROGGI G, Barresi V
    Assessment of CDKN2A/B homozygous deletion in gliomas: To FISH or not to FISH?
    J Neuropathol Exp Neurol. 2023 Jun 12:nlad045. doi: 10.1093.
    PubMed    
    
    
    May 2023
95. LE MK, Vuong HG, Nguyen TTT, Kondo T, et al
    NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas.
    J Neuropathol Exp Neurol. 2023 May 30:nlad037. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. LIU X, Zhao J, Wu Q, Wang L, et al
    ANKRD22 promotes glioma proliferation, migration, invasion, and epithelial-mesenchymal transition by upregulating E2F1-mediated MELK expression.
    J Neuropathol Exp Neurol. 2023 May 10:nlad034. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
97. GUBBIOTTI MA, Dhillon KS, Harris J, Kothari S, et al
    An unusual case of metastatic diffuse midline glioma in an adult.
    J Neuropathol Exp Neurol. 2023 Apr 19:nlad032. doi: 10.1093.
    PubMed    
    
    
    
98. YANG X, Ye Z, Zhang M, Ouyang Y, et al
    Tissue clearing to examine glioma complexity in 3 dimensions.
    J Neuropathol Exp Neurol. 2023 Apr 6:nlad024. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
99. PERSONS JE, Eschbacher KL
    A case of dedifferentiated meningeal solitary fibrous tumor.
    J Neuropathol Exp Neurol. 2023;82:367-369.
    PubMed    
    
    
    
100. CONG H, Guo X, Fan B, Liu Y, et al
     Dimethylation of histone H3 lysine 36 (H3K36me2) as a potential biomarker for glioma diagnosis, grading, and prognosis.
     J Neuropathol Exp Neurol. 2023 Mar 15:nlad016. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. BRANDEL MG, Goodwill VS, Park A, Snyder V, et al
     Sudden unexpected death from hydrocephalus due to cerebellopontine angle meningioma.
     J Neuropathol Exp Neurol. 2023 Mar 2:nlad014. doi: 10.1093.
     PubMed    
     
     
     February 2023
102. GUBBIOTTI MA, Santi M, Storm PB, Li M, et al
     First-time identification of a KIF5B-NTRK2 fusion in extraventricular neurocytoma.
     J Neuropathol Exp Neurol. 2023;82:272-275.
     PubMed    
     
     
     
103. KLEINSCHMIDT-DEMASTERS BK, Ormond DR
     Leptomeningeal metastases and dural spread in adult high-grade astrocytomas.
     J Neuropathol Exp Neurol. 2023;82:194-201.
     PubMed     Abstract available
     
     
     
104. KANG MK, Ahn SJ, Ha J, Park SH, et al
     Natural killer T-cell primary CNS lymphoma presenting as lymphomatosis cerebri: a case report and literature review.
     J Neuropathol Exp Neurol. 2023;82:261-266.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum